comparemela.com
Home
Live Updates
Eoepitopes Vacc No0010714785 - Breaking News
Pages:
Latest Breaking News On - Eoepitopes vacc no0010714785 - Page 1 : comparemela.com
Nykode Therapeutics Announces Presentation of Positive Immunogenicity Results from Phase 1/2a Study of VB10 NEO, an Individualized Therapeutic Cancer Vaccine, at the Neoantigen-Based Therapies Summit
VB10.NEO induced a T cell response in 95% of the patients, including expansion of both novel and pre-existing T cells The responses were broad, and the majority of the encoded neoepitopes were. | October 26, 2022
United states
Klaus edvardsen
Michael engsig
Agnete fredriksen
Roche group
Oslo stock exchange
Neoantigen based therapies summit
Chief executive officer
Chief development officer
Antigen presenting cells
Adaptive biotechnologies
Nykode therapeutics
Business officer
Nykode therapeutics as stock exchange
Press release
Eoepitopes vacc no0010714785
vimarsana © 2020. All Rights Reserved.